

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 413/06, A61K 31/42, C07D 471/04</b> <b>// (C07D 471/04, 221:00, 209:00)</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/38864</b>
			(43) International Publication Date: <b>5 August 1999 (05.08.99)</b>
(21) International Application Number: <b>PCT/US99/02210</b> (22) International Filing Date: <b>2 February 1999 (02.02.99)</b> (30) Priority Data: <b>09/017,517</b> <b>3 February 1998 (03.02.98)</b> <b>US</b> (71) Applicant: <b>AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).</b> (72) Inventors: <b>KELLY, Michael, Gerard; 19 Clinton Court, Plainsboro, NJ 08536 (US). GREENBLATT, Lynne, Padilla; 2 Northfield Court, Lambertville, NJ 08530 (US). NELSON, Frances, Christy; 694 Terrace Heights, Wyckoff, NJ 07481 (US).</b> (74) Agents: <b>ALICE, Ronald, W.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i>	
(54) Title: <b>OXAZOLE DERIVATIVES AS SEROTONIN-1A RECEPTOR AGONISTS</b>  <div style="text-align: center;">  </div> <div style="text-align: right;">(1)</div>			
(57) Abstract  <p>This invention provides compounds of Formula (1), wherein R<sub>1</sub> is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, benzyloxy, trifluoromethyl, chloro, bromo, or fluoro; a dashed line indicates an optional bond; X is NR<sub>4</sub>, or no atom; R<sub>2</sub> is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkylalkyl wherein the cycloalkyl moiety is 3-8 carbon atoms and the alkyl moiety is 1-6 carbon atoms, aryl of 5-12 carbon atoms, or arylalkyl of 6-12 carbon atoms; R<sub>3</sub> is aryl of 5-12 carbon atoms, arylalkyl of 6-12 carbon atoms, or heteroaryl of 5-12 ring atoms; R<sub>4</sub> is hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, which are useful in the treatment of psychosis (e.g. schizophrenia), anxiety, depression and related CNS disorders and other conditions such as the treatment of alcohol and drug withdrawal, sexual dysfunction and memory deficits associated with Alzheimer's disease and other dementias.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						


**OXAZOLE DERIVATIVES AS  
SEROTONIN-1A RECEPTOR AGONISTS**

**5 FIELD OF THE INVENTION**

This invention provides oxazole derivatives which are useful for the treatment of conditions related to or are affected by the 5-hydroxytryptamine-1A (5-HT<sub>1A</sub>) receptor subtype. The compounds are particularly useful for the treatment of psychosis (e.g. schizophrenia), anxiety, depression and related CNS disorders and other conditions  
 10 such as the treatment of alcohol and drug withdrawal, sexual dysfunction and memory deficits associated with Alzheimer's disease.

**DESCRIPTION OF THE INVENTION**

In accordance with this invention, there are compounds of Formula (1), having  
 15 the structure



(1)

20

wherein:

R<sub>1</sub> is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, benzyloxy, trifluoromethyl, chloro, bromo, or fluoro;

a dashed line indicates an optional bond;

25 X is NR<sub>4</sub>, or no atom;

R<sub>2</sub> is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkylalkyl wherein the cycloalkyl moiety is 3-8 carbon atoms and the alkyl moiety is 1-6 carbon atoms, aryl of 5-12 carbon atoms, or arylalkyl of 6-12 carbon atoms;

R<sub>3</sub> is aryl of 5-12 carbon atoms, arylalkyl of 6-12 carbon atoms, or heteroaryl of 5-12  
 30 ring atoms;


R<sub>4</sub> is hydrogen or alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof, which are useful in the treatment of psychosis (e.g. schizophrenia), anxiety, depression and related CNS disorders and other conditions such as the treatment of alcohol and drug withdrawal, sexual

- 2 -

dysfunction and memory deficits associated with Alzheimer's disease and other dementias.

- 5 The term alkyl includes both straight chain and branched alkyl moieties. The aryl, heteroaryl or aryl portion of arylalkyl may be optionally substituted. Two substituents on the aromatic ring may be connected together to form another ring system. An example of such a bicyclic system is an optionally substituted radical of the formula



- 10 (ie phenyl substituted by ethylenedioxy).

- It is preferred that the aryl or the aryl portion of the arylalkyl substituent has 6 to 10 carbon atoms and is most preferably a phenyl or 1,4-benzodioxan-5-yl group. The aryl or aryl portion may be optionally mono-, di-, or tri- substituted with a substituent  
15 selected from the group consisting of alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, chloro, fluoro, bromo, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, and dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms. It is preferred that the heteroaryl ring contains 1-3 heteroatoms the same or different selected from oxygen, nitrogen, and sulfur and specifically  
20 preferred heteroaryl substituents are pyridyl, furyl, thienyl, quinolinyl, isoquinolinyl, or indolyl. The heteroaryl moiety may be optionally mono-, di-, or tri- substituted with a substituent selected from the group consisting of alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, chloro, fluoro, bromo, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, and dialkylamino in which each of the  
25 alkyl groups is of 1-6 carbon atoms.


- The pharmaceutically acceptable salts are those derived from organic and inorganic acids such as, but not limited to: acetic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, hydrochloric, hydrobromic, phosphoric,  
30 nitric, sulfuric, methanesulfonic, toluenesulfonic and similarly known acceptable acids.

Of the compounds of this invention, preferred members include those in which  $R_2$  is alkyl, cycloalkyl, or cycloalkylalkyl; and those in which  $R_3$  is aryl, and more preferably phenyl.

- 3 -

This invention also provides processes for preparing the compounds of formula (1) which comprise one of the following:

- a) reacting a compound of formula (8)




(8)

wherein X, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and the dotted line are as defined above with a dehydrating agent,


or

- b) reacting a compound of formula (2)



(2)

wherein X and the dotted line are as defined above with a compound of formula (4)




(4)

wherein R<sub>2</sub> and R<sub>3</sub> are as defined above.


Compounds of the present invention may be conveniently prepared using conventional methods, utilizing for example the disconnections A and B shown in scheme 1 below.

- 4 -



Scheme 1

5 Aryl piperidines (2, X = no atom) and aryl-tetrahydropyridines (2, X = no atom) can be either commercially available, or alternatively can be readily prepared by those skilled in the art of organic synthesis, for example by the reaction of a suitably N-protected-4-piperidone with an aryl-lithium or aryl-magnesium compound as shown in scheme 2.




Scheme 2

10 In path A, the amidoalkyl chloride of formula (3) may be prepared from the corresponding amine (5) using standard acylating conditions known to those skilled in the art of organic synthesis.


15




- 5 -




The alkyl chloride (5) is readily available, and may be prepared from the corresponding protected amino acid (6) using, for example, the Arndt-Eistert reaction. For example, reaction of the acid chloride of (6) with diazomethane and treatment of the resulting  $\alpha$ -diazoketone (7) with HCl affords the required product.



Reaction of (2) with an alkyl chloride (3) affords the ketoamide (8). This product can be cyclized to the desired oxazole (1) by the action of a dehydrating agent such as the chlorinating agent  $\text{POCl}_3$ .



In path B, the chloroalkyloxazole (4) may be prepared from the ketoamide (3) by the action of a dehydrating agent such as  $\text{POCl}_3$ . The subsequent alkylation of (2) with the chloride (4) may be conducted in a suitable solvent (e.g. acetone), optionally utilizing a base (e.g. potassium carbonate or triethylamine) as an acid scavenger.



- 6 -

The compounds of this invention are 5-HT<sub>1A</sub> agonists. Affinity for the serotonin 5-HT<sub>1A</sub> receptor was established in a standard pharmacological test procedure which measures the compound's ability to displace [<sup>3</sup>H] 8-OH-DPAT binding in CHO cells stably transfected with human 5HT<sub>1A</sub> receptor. Stably transfected CHO cells are grown in DMEM containing 10% heat inactivated FBS and non-essential amino acids. Cells are scraped off the plate, transferred to centrifuge tubes, and washed twice by centrifugation (2000 rpm for 10 min., 4°C) in buffer (50 mM Tris pH 7.5). The resulting pellets are aliquoted and placed at -80°C. On the day of assay, the cells are thawed on ice and resuspended in buffer. The binding assay is performed in a 96 well microtiter plate in a total volume of 250 µL. Non-specific binding is determined in the presence of 10 mM 5HT, final ligand concentration is 1.5 nM. Following a 30 minute incubation at room temperature, the reaction is terminated by the addition of ice cold buffer and rapid filtration through a GF/B filter presoaked for 30 minutes in 0.5% PEI. Compounds are initially tested in a single point assay to determine percent inhibition at 1, 0.1, and 0.01 mM, and K<sub>i</sub> values are determined for the active compounds.

A representative compound of this invention, the compound of Example 9, was evaluated in the standard pharmacological test procedure described above, and had a K<sub>i</sub> of 4.4 nM, which demonstrates a high affinity for the 5-HT<sub>1A</sub> receptor. Based on the results of obtained in the standard pharmacological test procedure, the compounds of this invention are useful in the treatment of central nervous system disorders such as depression, anxiety, sleep disorders, sexual dysfunction, alcohol and cocaine addiction, cognition enhancement and related problems in addition to the treatment of Alzheimer's disease, Parkinson's disease, obesity and migraine.

The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium

- 7 -

carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or  
5 suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples  
10 of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily  
15 ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be  
20 either liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or  
25 sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

The therapeutically effective dosage to be used in the treatment of a specific psychosis must be subjectively determined by the attending physician. The variables  
30 involved include the specific psychosis or state of anxiety and the size, age and response pattern of the patient. In therapeutic treatment, projected daily dosages of the compounds of this invention are 0.1-2000 mg/kg for oral administration, preferably 0.5-500 mg/kg; and 0.1-100 mg/kg for parenteral administration, preferably 0.5-50 mg/kg.

35

- 8 -

The following non-limiting examples illustrate the preparation of representative compounds of this invention.

### Example 1

#### 5        N-Cyclohexanoyl-L-Phenylalanylchloromethylketone

A cooled (-10°C) mixture containing L-phenylalanylchloromethylketone (3.2 mmole) in CH<sub>2</sub>Cl<sub>2</sub> (30 ml) and potassium carbonate (10 mmole) in water (10 ml) was treated with cyclohexanecarbonylchloride (3.2 mmole). The resulting mixture was stirred for two  
10 hours at ambient temperature. The organic layer was separated, washed with water (3 x 20 ml) and dried over anhydrous magnesium sulfate. Filtration and concentration *in vacuo* gave the titled compound as a cream colored solid (2.6 mmole, 81%).

Elemental Analysis for: C<sub>17</sub>H<sub>22</sub>ClNO<sub>2</sub>

Calculated:     C, 66.33; H, 7.20; N, 4.55

15    Found:        C, 66.12; H, 7.12; N, 4.34

### Example 2

#### 4-Benzyl-5-chloromethyl-2-cyclohexyloxazole

20 Under a nitrogen atmosphere, a benzene solution (26 ml) of the chloromethylketone (2.6 mmole) from example 1 was treated with dimethylformamide (2 ml) and phosphorous oxychloride (26 mmole). The mixture was heated to reflux for 15 minutes while water was collected in a Dean-Stark apparatus. After cooling to room temperature, the reaction mixture was poured onto ice (25 g), the solution made basic  
25 with sodium bicarbonate and the product was extracted with ethyl acetate (2 x 30 ml). The combined organics were washed with water (2 x 30 ml), dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo* to afford the crude product. This was purified by silica-gel flash chromatography, eluting with dichloromethane, to afford the titled product as a light yellow oil (1.03 mmole, 40 %).

30    Elemental Analysis for: C<sub>17</sub>H<sub>20</sub>ClNO

Calculated:     C, 70.46; H, 6.96; N, 4.83

Found:        C, 70.35; H, 7.12; N, 5.02

- 9 -

**Example 3****N-Pivaloyl-L-Phenylalanylchloromethylketone**

5 The titled compound was isolated in 80% yield when pivaloyl chloride (5 mmole) was used in the procedure outlined in example 1 above.

Elemental Analysis for:  $C_{15}H_{20}ClNO_2$

Calculated: C, 63.94; H, 7.15; N, 4.97

Found: C, 64.23; H, 7.27; N, 5.12

10

**Example 4****4-Benzyl-5-chloromethyl-2-tertbutyloxazole**

15 The title compound was prepared using N-pivalyl-L-phenylalanylchloromethyl ketone (4 mmole) in the procedure described in example 2. The product was obtained as a light yellow oil (2.24 mmole, 56% yield) after  $SiO_2$  "flash" Chromatography.

Elemental Analysis for:  $C_{15}H_{18}ClNO$

Calculated: C, 68.30; H, 6.88; N, 5.31

Found: C, 68.52; H, 7.02; N, 5.42

20

**Example 5****N-Benzoyl-L-Phenylalanylchloromethylketone**

25 The titled compound was prepared in 88% yield by substituting benzoyl chloride (5 mmole) into the procedure outlined in example 1 above. The product (4.4 mmole) was obtained as a yellow oil, and was used without further purification.

Elemental Analysis for:  $C_{17}H_{16}ClNO_2$

Calculated: C, 67.66; H, 5.34; N, 4.64

Found: C, 67.55; H, 5.30; N, 4.54

30

**Example 6****4-Benzyl-5-chloromethyl-2-phenyloxazole**

35 The title compound was prepared using N-benzoyl-L-phenylalanylchloromethylketone (4.4 mmole) in the procedure described in example 2. The product was obtained as a light yellow oil (1.4 mmole, 32% yield) after  $SiO_2$  "flash" Chromatography.

- 10 -

Elemental Analysis for: C<sub>17</sub>H<sub>14</sub>CINO

Calculated: C, 71.96; H, 4.97; N, 4.94

Found: C, 72.25; H, 5.15; N, 5.23

5

### Example 7

#### N-Cyclohexaneacetyl-L-Phenylalanylchloromethylketone

10 The compound was prepared in 83% yield by substituting cyclohexylacetyl chloride (3 mmole) into the procedure outlined in example 1 above. This provided the titled compound as a light yellow oil (2.5 mmole) which was used without further purification.

Elemental Analysis for: C<sub>18</sub>H<sub>24</sub>CINO<sub>2</sub>

Calculated: C, 67.17; H, 7.52; N, 4.35

15 Found: C, 67.35; H, 7.50; N, 4.51

### Example 8

#### 4-Benzyl-5-chloromethyl-2-cyclohexylmethyloxazole

20 The title compound was prepared using N-cyclohexaneacetyl-L-phenylalanyl-chloromethyl ketone (2.5 mmole) in the procedure described in example 2. The product was obtained as a light yellow oil (1.2 mmole, 48% yield) after SiO<sub>2</sub> "flash" Chromatography.

Elemental Analysis for: C<sub>18</sub>H<sub>22</sub>CINO

25 Calculated: C, 71.16; H, 7.30; N, 4.61

Found: C, 71.23; H, 7.45; N, 4.65

### Example 9

#### 1-(4-Benzyl-2-cyclohexyl-oxazol-5-ylmethyl)- 4-(2-methoxy-phenyl)-piperidine

30 A suspension of 4-(2-methoxy-phenyl)-piperidine (0.19 g, 1.0 mmole), potassium carbonate (0.345 g, 2.5 mmole), potassium iodide (0.066 g, 0.4 mmole) and 4-benzyl-5-chloromethyl-2-cyclohexyloxazole (0.244 g, 0.85 mmole) from example 2, in acetone (15 ml), was stirred at ambient temperature for 16 hours. The solvent was  
35 removed *in vacuo*, water (50 ml) added and the product extracted into CH<sub>2</sub>Cl<sub>2</sub> (3 x 50 ml). The combined organics were washed with water (50 ml), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* and the product (0.415 g) purified

- 11 -

by "flash" chromatography over silica gel (1% MeOH/CHCl<sub>3</sub>) to afford a colorless oil (0.376 g, 99% yield). An ethanolic solution of the product was treated with 1 equivalent of fumaric acid in ethanol (2 ml) to afford the titled compound as a white crystalline solid.

5 mp 170-171°C

Elemental Analysis for: C<sub>29</sub>H<sub>36</sub>N<sub>2</sub>O<sub>2</sub> 1.0C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>

Calculated: C, 70.69; H, 7.19; N, 5.00

Found: C, 70.41; H, 7.18; N, 4.96

10

### Example 10

#### 2-(4-Benzyl-2-cyclohexyl-oxazol-5-ylmethyl)- 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole

A suspension of 1,2,3,4-tetrahydro-9H-pyrido(3,4-B)indole (0.172 g, 1.0 mmole), potassium carbonate (0.345 g, 2.5 mmole), potassium iodide (0.066 g, 0.4 mmole) and  
15 4-benzyl-5-chloromethyl-2-cyclohexyloxazole (0.289 g, 1.0 mmole) from example 2, in acetone (13 ml), was stirred at ambient temperature for two hours. The solvent was removed *in vacuo*, water (50 ml) added and the product extracted into CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 ml). The combined organics were washed with water (50 ml), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* and the product (0.401 g) purified  
20 by "flash" chromatography over silica gel (2% MeOH/CHCl<sub>3</sub>) to afford a colorless oil (0.256 g, 60% yield). An ethanolic solution of the product was treated with 0.5 equivalents of fumaric acid in ethanol (2 ml) to afford the titled compound as an off white crystalline solid.

mp 200-201°C

25 Elemental Analysis for: C<sub>28</sub>H<sub>31</sub>N<sub>3</sub>O 0.5C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>

Calculated: C, 74.51; H, 6.88; N, 8.69

Found: C, 74.28; H, 6.91; N, 8.59

### Example 11

#### 1-(4-Benzyl-2-tert-butyl-oxazol-5-ylmethyl)- 4-(2-methoxy-phenyl)-piperidine

A suspension of 4-(2-methoxy-phenyl)-piperidine (0.19 g, 1.0 mmole), potassium carbonate (0.345 g, 2.5 mmole), potassium iodide (0.066 g, 0.4 mmole) and 4-benzyl-  
35 5-chloromethyl-2-tertbutyloxazole (0.263 g, 1.0 mmole) from example 4, in acetone (15 ml), was stirred at ambient temperature for 12 hours. The solvent was removed *in vacuo*, water (50 ml) added and the product extracted into CH<sub>2</sub>Cl<sub>2</sub> (3 x 50 ml). The combined organics were washed with water (50 ml), dried over anhydrous sodium

- 12 -

sulfate, filtered and concentrated *in vacuo* and the product (0.4 g) purified by "flash" chromatography over silica gel (1% MeOH/CHCl<sub>3</sub>) to afford a colorless oil (0.32 g, 76% yield). An ethanolic solution of the product was treated with 1 equivalent of ethereal HCl to afford the titled compound as a white crystalline solid.

5 Elemental Analysis for: C<sub>27</sub>H<sub>34</sub>N<sub>2</sub>O<sub>2</sub> 1.0HCl

Calculated: C, 71.27; H, 7.75; N, 6.16

Found: C, 71.45; H, 7.98; N, 6.36

### Example 12

10 2-(4-Benzyl-2-cyclohexylmethyl-oxazol-5-ylmethyl)-  
15 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole

A suspension of 1,2,3,4-tetrahydro-9H-pyrido(3,4-B)indole (0.172 g, 1.0 mmole), potassium carbonate (0.345 g, 2.5 mmole), potassium iodide (0.066 g, 0.4 mmole) and 4-benzyl-5-chloromethyl-2-cyclohexylmethyloxazole (0.303 g, 1.0 mmole) from  
15 example 8, in acetone (15 ml), was stirred at ambient temperature for 16 hours. The solvent was removed *in vacuo*, water (50 ml) added and the product extracted into CH<sub>2</sub>Cl<sub>2</sub> (2 x 20 ml). The combined organics were washed with water (50 ml), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* and the product (0.401 g) purified by "flash" chromatography over silica gel (2% MeOH/CHCl<sub>3</sub>) to  
20 afford a colorless oil (0.299 g, 68% yield). An ethanolic solution of the product was treated with ethereal HCl to afford the titled compound as an off white crystalline solid.

Elemental Analysis for: C<sub>29</sub>H<sub>33</sub>N<sub>3</sub>O 1.0HCl

Calculated: C, 73.17; H, 7.20; N, 8.83


Found: C, 73.28; H, 7.41; N, 8.89



- 13 -

## WHAT IS CLAIMED IS:

1. A compound of Formula 1 having the structure



wherein:

R<sub>1</sub> is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, benzyloxy, trifluoromethyl, chloro, bromo, or fluoro;

a dashed line indicates an optional bond;

X is NR<sub>4</sub>, or no atom;

R<sub>2</sub> is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkylalkyl wherein the cycloalkyl moiety is 3-8 carbon atoms and the alkyl moiety is 1-6 carbon atoms, aryl of 5-12 carbon atoms, or arylalkyl of 6-12 carbon atoms;

R<sub>3</sub> is aryl of 5-12 carbon atoms, arylalkyl of 6-12 carbon atoms, or heteroaryl of 5-12 ring atoms;

R<sub>4</sub> is hydrogen or alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R<sub>3</sub> is aryl of 5-12 carbon atoms.


3. The compound of claim 1 or claim 2, wherein R<sub>2</sub> is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, or cycloalkylalkyl wherein the cycloalkyl moiety is 3-8 carbon atoms and the alkyl moiety is 1-6 carbon atoms.

4. The compound according to claim 1, which is 1-(4-benzyl-2-cyclohexyloxazol-5-ylmethyl)-4-(2-methoxy-phenyl)-piperidine or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, which is 1-(4-benzyl-2-cyclohexyloxazol-5-ylmethyl)-4-(2-methoxy-phenyl)-piperidine fumarate.

- 14 -

6. The compound according to claim 1, which is 2-(4-benzyl-2-cyclohexyl-oxazol-5-ylmethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1, which is 2-(4-benzyl-2-cyclohexyl-oxazol-5-ylmethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole fumarate.
8. The compound according to claim 1, which is 1-(4-benzyl-2-tert-butyl-oxazol-5-ylmethyl)-4-(2-methoxy-phenyl)-piperidine or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 1, which is 1-(4-benzyl-2-tert-butyl-oxazol-5-ylmethyl)-4-(2-methoxy-phenyl)-piperidine hydrochloride.
10. The compound according to claim 1, which is 2-(4-benzyl-2-cyclohexylmethyl-oxazol-5-ylmethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 1, which is 2-(4-benzyl-2-cyclohexylmethyl-oxazol-5-ylmethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole hydrochloride.
12. A method of treating anxiety in a mammal in need thereof which comprises administering to said mammal a compound of Formula 1 having the structure



(1)

wherein:

$R_1$  is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, benzyloxy, trifluoromethyl, chloro, bromo, or fluoro;

a dashed line indicates an optional bond;

X is  $NR_4$ , or no atom;

$R_2$  is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkylalkyl wherein the cycloalkyl moiety is 3-8 carbon atoms and the alkyl moiety is 1-6 carbon atoms, aryl of 5-12 carbon atoms, or arylalkyl of 6-12 carbon atoms;

- 15 -


R<sub>3</sub> is aryl of 5-12 carbon atoms, arylalkyl of 6-12 carbon atoms, or heteroaryl of 5-12 ring atoms;

R<sub>4</sub> is hydrogen or alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

5

13. A method of treating depression in a mammal in need thereof which comprises administering to said mammal a compound of Formula 1 having the structure



10 wherein:

R<sub>1</sub> is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, benzyloxy, trifluoromethyl, chloro, bromo, or fluoro;

a dashed line indicates an optional bond;

X is NR<sub>4</sub>, or no atom;


15 R<sub>2</sub> is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkylalkyl wherein the cycloalkyl moiety is 3-8 carbon atoms and the alkyl moiety is 1-6 carbon atoms, aryl of 5-12 carbon atoms, or arylalkyl of 6-12 carbon atoms;

R<sub>3</sub> is aryl of 5-12 carbon atoms, arylalkyl of 6-12 carbon atoms, or heteroaryl of 5-12 ring atoms;

20 R<sub>4</sub> is hydrogen or alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

14. A method of treating Alzheimer's disease, cognitive disorders, dementias, sleep disorders, drug, alcohol addiction, or panic disorders in a mammal in need thereof which comprises administering to said mammal a compound of Formula 1 having the structure



wherein:

30 R<sub>1</sub> is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, benzyloxy, trifluoromethyl, chloro, bromo, or fluoro;

a dashed line indicates an optional bond;

- 16 -

X is  $\text{NR}_4$ , or no atom;


$\text{R}_2$  is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkylalkyl wherein the cycloalkyl moiety is 3-8 carbon atoms and the alkyl moiety is 1-6 carbon atoms, aryl of 5-12 carbon atoms, or arylalkyl of 6-12 carbon atoms;

5  $\text{R}_3$  is aryl of 5-12 carbon atoms, arylalkyl of 6-12 carbon atoms, or heteroaryl of 5-12 ring atoms;

$\text{R}_4$  is hydrogen or alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

10 15. A pharmaceutical composition which comprises a compound of Formula 1 having the structure



wherein:

15  $\text{R}_1$  is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, benzyloxy, trifluoromethyl, chloro, bromo, or fluoro;

a dashed line indicates an optional bond;

X is  $\text{NR}_4$ , or no atom;

$\text{R}_2$  is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkylalkyl wherein the cycloalkyl moiety is 3-8 carbon atoms and the alkyl moiety is 1-6 carbon atoms, aryl of 5-12 carbon atoms, or arylalkyl of 6-12 carbon atoms;

20  $\text{R}_3$  is aryl of 5-12 carbon atoms, arylalkyl of 6-12 carbon atoms, or heteroaryl of 5-12 ring atoms;

$\text{R}_4$  is hydrogen or alkyl of 1-6 carbon atoms;

25 or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier.

16. A compound as claimed in any one of Claims 1 to 11 for use as a medicament.

17. Use of a compound as claimed in any one of Claims 1 to 11 in the preparation  
30 of a medicament for the treatment of a disease condition related to or affected by the 5-hydroxytryptamine-1A (5-HT<sub>1A</sub>) receptor subtype.


18. Use of a compound as claimed in any one of Claims 1 to 11 in the preparation of a medicament for the treatment of anxiety, depression, Alzheimer's disease,

- 17 -

cognitive disorders, dementias, sleep disorders, drug addiction, alcohol addiction, or panic disorders.

19. A process for preparing a compound of formula 1 as claimed in claim 1 which comprises one of the following:

a) reacting a compound of formula (8)




(8)

wherein X, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and the dotted line are as defined in claim 1 with a dehydrating agent to give a compound of formula (1),


or

b) reacting a compound of formula (2)



(2)

wherein X and the dotted line are as defined in claim 1 with a compound of formula (4)



(4)

wherein R<sub>2</sub> and R<sub>3</sub> are as defined in claim 1 to give a compound of formula (1).

# INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 99/02210

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D413/06 A61K31/42 C07D471/04 //(C07D471/04,221:00,  
209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 162 322 A (TAYLOR JR CHANDLER R ET AL) 10 November 1992 see the whole document	1,12-18
A	EP 0 356 098 A (GLAXO GROUP LTD) 28 February 1990 see the whole document	1,12-18

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 May 1999

Date of mailing of the international search report

20/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 02210

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12-14  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 12-14  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/02210

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5162322 A	10-11-1992	NONE	
EP 0356098 A	28-02-1990	AT 111910 T	15-10-1994
		AU 2174288 A	09-03-1989
		DE 3851597 D	27-10-1994
		DE 3851597 T	26-01-1995
		EP 0306323 A	08-03-1989
		ES 2060655 T	01-12-1994
		HK 75591 A	04-10-1991
		HU 9500522 A	30-10-1995
		IE 61669 B	16-11-1994
		IL 87658 A	24-06-1994
		JP 2167280 A	27-06-1990
		LV 5737 A	20-06-1996
		PH 25493 A	24-07-1991
		US 5008272 A	16-04-1991
		US 5360800 A	01-11-1994